Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohortStrong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readouts for givastomig ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology

ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB), a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in 24th Annual Needham Virtual Healthcare Conference, being held April 7-10, 2025. Details are as follows: 24th Annual Needham Virtual Healthcare Conference Conference Date:April 7-10, 2025Format:Company Presentation and one-on-one meetingsPresentation Time:Monday, April 7, 2025, 8:45 to 9:25 AM ETWebcast Link:Register here   About I-Mab I-Mab (NASDAQ:IMAB) is a US-based, global biotech company, focused on the developm

ROCKVILLE, Md., March 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) ("I-Mab" or the "Company"), announced today that on March 19, 2025 it received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the $1.00 minimum bid price requirement under the Nasdaq Listing Rules (the "Listing Rules"). Based on the closing bid price of the Company's listed securities for the period from February 3, 2025 to March 18, 2025, the Company has not met the minimum bid price requirement set forth in Listing Rule 5450(a)(1) during that period. The Notice is only a notification of deficienc

Siebert Williams Shank initiated coverage of I-Mab with a rating of Buy and set a new price target of $96.00

Needham reiterated coverage of I-MAB with a rating of Buy and set a new price target of $85.00 from $83.00 previously

HC Wainwright & Co. reiterated coverage of I-MAB with a rating of Buy and set a new price target of $95.00 from $75.00 previously

6-K - I-Mab (0001778016) (Filer)

6-K - I-Mab (0001778016) (Filer)

20-F - I-Mab (0001778016) (Filer)

Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohortStrong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readouts for givastomig ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology

Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritizationThe Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40-patient dose expansion study is now underway with data expected in early 2026Cash balance of $184.4 million (as of September 30, 2024), expected to support operations into 2027, complemented by a strengthened U.S.-based leadership team and streamlined operating modelROCKVILLE, MD, Jan. 6, 2025 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based,

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy dataOn track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024Estimated cash runway into 2027, based on $184.4 million in cash and cash equivalents, and short-term investments as of September 30, 2024ROCKVILLE, Md., Nov. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the three and nine months ended

ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time. The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year fin

Completed divestiture of China operationsUliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody)Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific)Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific)Well-positioned for pipeline advancement with $207.5 million in cash and cash equivalents, and short-term investments as of June 30, 2024, and cash runway expected into 2027I-Mab will hold a conference call and webcast today, August 28th, at 8:00 AM ETROCKVILLE, Md., Aug. 28, 2024 /PRNews

Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to host a conference call and webcast on Wednesday, August 28, 2024, 8:00 AM ET to discuss financial results, pipeline progress and recent business highlights for the half year ended June 30, 2024.

SC 13G/A - I-Mab (0001778016) (Subject)

SC 13G/A - I-Mab (0001778016) (Subject)

SC 13D - I-Mab (0001778016) (Subject)